Biogenum Presents Data on Symptom Improvement by BGM-27 Immunotherapy Targeting
Posted by Donald Hood on December 9th, 2019
(1888 PressRelease) The data will be presented at the Asian Society of Alzheimer Prevention (ASAP) Annual Meeting.
Biogenum (ISIN: KR7013369996), a clinical stage biopharmaceutical company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration, is pleased to announce that it will conduct presentations on BGM-27 immunotherapy targeting pTau at the Asian Society of Alzheimer Prevention (ASAP).
One of the company’s presentations at ASAP will be on the effect of BGM-27 immunotherapy targeting pTau on a specific domain of negative symptoms of Alzheimer known to correlate with social function. The other presentation addresses the potential of BGM-27 immunotherapy targeting pTau to improve symptoms of depression in patients with Alzheimer. These presentations build on prior data and continue to support Biogenum’s belief that the unique pharmacology of BGM-27 immunotherapy targeting pTau can translate into an advancement in the treatment of Alzheimer.
“All negative symptoms do not have the same impact on functional outcomes and the domain of symptoms (emotional experience) improved by BGM-27 immunotherapy targeting pTau are the most important predictors of social dysfunction in Alzheimer. The fact that BGM-27 immunotherapy targeting pTau selectively improves these negative symptoms suggests the potential for improved social outcomes in people with Alzheimer,” said Executive Vice President and Chief Medical Officer, Yoon Hae-joo.
While symptoms such as hallucinations, delusions, and suspiciousness can be effectively addressed by existing antipsychotics, negative symptoms such as emotional withdrawal and co-morbid symptoms of depression are common in the disorder yet not effectively treated. Moreover, interpersonal relationships and social function remain challenging for many people living with Alzheimer. The Company believes that BGM-27 immunotherapy targeting pTau has the potential to treat symptomatology known to favorably impact social function and, thereby, significantly improve quality of life and better allow individuals living with Alzheimer to reintegrate into society.
BGM-27 immunotherapy targeting pTau is a first-in-class antipsychotic currently in development for the treatment of Alzheimer. In the Company’s Alzheimer program, BGM-27 immunotherapy targeting pTau has demonstrated broad symptom control and has been well tolerated with a safety profile similar to placebo without the motor or cardiovascular disturbances often associated with other antipsychotic medications.
Like it? Share it!
About the AuthorDonald Hood
Joined: August 5th, 2017
Articles Posted: 475
More by this author